Latent Autoimmune Diabetes in Adults (LADA): Symptoms, Causes, and Treatment

If you have been diagnosed with Type 2 diabetes but your blood sugar remains difficult to control despite medication and lifestyle changes, there may be more to the picture. A condition called LADA, or Latent Autoimmune Diabetes in Adults, is far more common than most people realise, and it is frequently mistaken for Type 2 diabetes. Understanding what LADA is, how it behaves, and how it should be treated can make a significant difference to long-term health outcomes.

What Is LADA Diabetes?

LADA, which stands for Latent Autoimmune Diabetes in Adults, is a form of diabetes caused by an autoimmune process in which the body's immune system gradually attacks and destroys the insulin-producing beta cells in the pancreas. Over time, this leads to declining insulin production and rising blood sugar levels.

What makes LADA distinct is its pace. Unlike type 1 diabetes, where beta cell destruction happens rapidly, LADA progresses slowly, sometimes over several years. This means that at the time of diagnosis, a person may still be producing some insulin and may not yet need insulin injections. This slow progression is what gives LADA its name: the word "latent" reflects that the autoimmune process is present but developing gradually.

LADA is sometimes referred to as Type 1.5 diabetes because it sits between Type 1 and Type 2 in several important ways. It is typically diagnosed in adults between the ages of 30 and 50. Studies suggest that between 4% and 12% of people initially diagnosed with Type 2 diabetes may actually have LADA, meaning millions of people worldwide may be living with a misdiagnosis.

Why LADA Is Called Type 1.5 Diabetes

The term Type 1.5 diabetes captures something important about the nature of LADA. It shares the autoimmune mechanism of type 1 diabetes, where the immune system mistakenly targets the pancreas, but its presentation and progression resemble Type 2 diabetes in many ways.

Because LADA develops in adulthood and progresses slowly, it does not trigger the sudden, dramatic symptoms that often accompany a Type 1 diagnosis in childhood or adolescence. Blood sugar levels rise gradually, the person may initially respond to oral medications, and there are no obvious signs pointing to an autoimmune cause. This leads many clinicians to diagnose it as Type 2, particularly when antibody testing is not routinely performed.

The "1.5" label is not an official medical classification, but it has become widely used because it communicates the hybrid nature of the condition clearly. It is also sometimes described as adult onset autoimmune diabetes or slow onset type 1 diabetes, both of which reflect its true nature more accurately than a Type 2 label.

How LADA Differs From Type 1 and Type 2 Diabetes

Who Is at Risk of LADA?

LADA can affect any adult, but certain factors increase the likelihood of developing it.

• Adults between 30 and 50 years of age are most commonly affected, though it can develop outside this range
• People with a family history of type 1 diabetes or other autoimmune conditions carry a higher genetic risk
• Individuals with specific genetic markers, particularly HLA-DR3 and HLA-DR4, which are also associated with Type 1 diabetes, have an increased susceptibility
• Those with a personal history of other autoimmune conditions such as thyroid disease, coeliac disease, or rheumatoid arthritis face a higher risk
• People who are lean or of normal weight at the time of a diabetes diagnosis, particularly if they do not have the typical metabolic profile of Type 2 diabetes
• Individuals whose blood sugar proves difficult to manage with oral medications despite adhering closely to a treatment plan
• Those whose symptoms progress faster than expected for a Type 2 diagnosis

Causes of Latent Autoimmune Diabetes in Adults

LADA is an autoimmune condition, which means it arises from a malfunction in the immune system rather than from lifestyle choices or external triggers. Several factors are thought to contribute.

Autoimmune Attack on Beta Cells

The defining cause of LADA is the production of autoantibodies, particularly glutamic acid decarboxylase (GAD) antibodies, that target and gradually destroy insulin-producing beta cells in the pancreas. As more beta cells are lost over time, insulin production falls and blood sugar rises.

Genetic Predisposition

LADA shares several genetic risk factors with type 1 diabetes, including specific variations in the HLA gene complex. Having a parent or sibling with Type 1 diabetes or another autoimmune condition increases the risk. Genetics alone, however, does not guarantee that LADA will develop.

Environmental Triggers

While the exact triggers are not fully understood, environmental factors are thought to play a role in activating the autoimmune response in genetically susceptible individuals. Viral infections, in particular, have been studied as possible initiating factors, as have dietary components and gut microbiome changes.

Overlap With Metabolic Risk

Some people with LADA also carry features of insulin resistance, particularly if they are overweight. This further complicates diagnosis, as it can make the condition look like straightforward Type 2 diabetes on the surface.

Common Symptoms of LADA Diabetes

The symptoms of LADA often appear similar to those of Type 2 diabetes, especially in the early stages. This is a key reason why the condition is so commonly misdiagnosed.

Symptoms Common to Both LADA and Type 2

• Increased thirst and dry mouth
• Frequent urination
• Fatigue and low energy
• Blurred vision
• Itchy or dry skin
• Slow-healing cuts or wounds
• Recurrent infections

Features That May Suggest LADA Rather Than Type 2

• Unexplained weight loss, particularly in a person who is already lean or of normal weight
• Symptoms that progress more quickly than expected for a Type 2 diagnosis
• Blood sugar levels that remain persistently high despite oral medication and dietary changes
• Onset in a younger adult without significant obesity or metabolic risk factors
• A personal or family history of autoimmune conditions

Because LADA often presents subtly and slowly, it is easy to overlook the signs that point beyond a simple Type 2 diagnosis. If you have been told you have Type 2 diabetes but your treatment is not working as expected, it is worth raising this with your doctor.

How LADA Is Diagnosed

Diagnosing LADA requires more than a standard blood glucose test. Because the condition is frequently misidentified as Type 2 diabetes, specific investigations must be carried out to confirm the autoimmune nature of the condition.

The three criteria typically used to identify LADA are adult onset, usually after the age of 30; the presence of circulating autoantibodies; and no requirement for insulin for at least six months after diagnosis.

Tests Used in Diagnosis

• Blood glucose test to confirm diabetes, with a fasting result of 126 mg/dL or higher indicating the condition
• HbA1c test, which reflects average blood sugar over the past two to three months, helping to assess the degree of glucose dysregulation and establish a baseline for monitoring
• GAD antibodies test, which checks for glutamic acid decarboxylase autoantibodies in the blood, the most reliable diagnostic marker for LADA; a positive result strongly indicates an autoimmune process affecting the pancreas
• C-peptide test, which measures how much insulin the pancreas is still producing; low or declining C-peptide levels are consistent with LADA
• Additional autoantibody tests such as IA-2 or ZnT8 antibodies may also be checked in some cases

LADA should be suspected in any adult with a new diabetes diagnosis who is lean, does not have the typical metabolic features of Type 2, has a personal or family history of autoimmune disease, or whose blood sugar does not respond adequately to oral medication.

Treatment Options for LADA Diabetes

Managing LADA requires a treatment plan that evolves as the condition progresses. What works in the early stages will not necessarily be sufficient as beta cell function declines.

Early Stage Management

In the initial months after diagnosis, when some insulin production remains, oral diabetes medications may help manage blood sugar. However, not all medications are equally appropriate.

Metformin is generally considered safe and is often used in early LADA management. Sulfonylureas, however, are typically avoided because they stimulate the remaining beta cells to produce more insulin, which may accelerate their destruction and hasten the need for insulin therapy.

Some experts advocate starting insulin therapy early, even before it becomes strictly necessary, to help preserve remaining beta cell function. The evidence for this approach continues to be studied.

Insulin Therapy

As beta cells are progressively destroyed, insulin production declines and oral medications become insufficient. Most people with LADA will require insulin therapy within five years of diagnosis, though this varies. A basal-bolus insulin regimen, combining long-acting background insulin with short-acting mealtime insulin, is commonly used to achieve stable glucose control.

Insulin pump therapy may be an option for some individuals, offering more precise and flexible dosing.

Blood Sugar Monitoring

Regular blood glucose monitoring is essential throughout the course of LADA. A continuous glucose monitor (CGM) can provide real-time data to help manage fluctuations and detect hypoglycaemia, particularly once insulin therapy is initiated.

Multidisciplinary Care

Working with an endocrinologist, diabetes nurse educator, and dietitian provides the most comprehensive support. Treatment plans need to be reviewed regularly as the condition progresses and insulin requirements change.

Complications Associated With LADA

The most significant risk associated with LADA arises from misdiagnosis or delayed diagnosis. When treated as Type 2 diabetes without the appropriate investigations, a person with LADA may receive inadequate treatment for years, during which time blood sugar remains poorly controlled and complications develop silently.

Long-term, poorly managed blood sugar in LADA carries the same risks as in any form of diabetes.

• Kidney damage, or nephropathy, which can progress to chronic kidney disease
• Eye damage, or retinopathy, which can impair vision and, without treatment, lead to blindness
• Nerve damage, or neuropathy, causing pain, tingling, numbness, or weakness in the limbs
• Cardiovascular disease, including increased risk of heart attack and stroke
• Diabetic ketoacidosis (DKA), a serious and potentially life-threatening complication that occurs when the body breaks down fat for energy due to insufficient insulin, producing harmful ketone acids in the blood

The risk of DKA increases as beta cell function declines and insulin production becomes inadequate. Recognising LADA early and transitioning to insulin therapy at the right time are the most important steps in preventing these outcomes.

Lifestyle Management and Diet Tips

While LADA is an autoimmune condition that cannot be managed through lifestyle alone, daily habits play an important role in supporting blood sugar stability and overall health.

• Follow a structured diabetes diet plan that emphasises complex carbohydrates, lean protein, healthy fats, and fibre-rich vegetables to help reduce glucose spikes
• Eat at regular intervals and avoid skipping meals, as inconsistent eating patterns make blood sugar harder to manage
• Limit refined sugars, sugary drinks, white bread, and processed foods that cause rapid rises in blood glucose
• Engage in regular moderate physical activity such as walking, swimming, or cycling, which improves insulin sensitivity and supports cardiovascular health
• Avoid high-intensity exercise without checking blood sugar first, as physical activity can cause unexpected fluctuations particularly once insulin is involved
• Manage stress through relaxation techniques such as meditation, yoga, or deep breathing, since stress hormones directly affect blood glucose levels
• Maintain a healthy weight, as excess weight can worsen insulin resistance and complicate management
• Avoid smoking, which worsens cardiovascular risk and impairs blood sugar control
• Limit alcohol intake, as it interferes with glucose regulation and can mask symptoms of hypoglycaemia
• Keep a record of blood sugar readings, meals, and activity levels to share with your healthcare team for informed treatment adjustments

When to Consult a Doctor

If you have been diagnosed with Type 2 diabetes and your blood sugar remains difficult to control despite following your treatment plan, speak to your doctor about the possibility of LADA. This is particularly important if you are lean, younger than 50, have a personal or family history of autoimmune conditions, or have never had the typical metabolic risk factors associated with Type 2 diabetes.

Seek immediate medical attention if you develop symptoms of diabetic ketoacidosis, including nausea, vomiting, abdominal pain, fruity-smelling breath, rapid breathing, or confusion. DKA is a medical emergency that requires urgent hospital care.

If you have not yet been diagnosed but are experiencing persistent thirst, frequent urination, unexplained weight loss, or fatigue that is not improving, please see a doctor promptly. Early diagnosis of any form of diabetes leads to better outcomes.

Key Takeaways

• LADA is an autoimmune form of diabetes that develops slowly in adults, often between the ages of 30 and 50
• It shares the autoimmune mechanism of type 1 diabetes but progresses gradually like Type 2, earning it the name Type 1.5 diabetes
• It is estimated that 4% to 12% of people diagnosed with Type 2 diabetes may actually have LADA
• The presence of GAD autoantibodies is the most reliable diagnostic marker and distinguishes LADA from Type 2 diabetes
• Oral medications may work initially, but most people with LADA will eventually require insulin therapy as beta cell function declines
• Misdiagnosis and inadequate treatment increase the risk of serious long-term diabetes complications
• Lifestyle modifications including diet, regular exercise, and stress management support blood sugar stability alongside medical treatment
• LADA cannot be prevented, but early and accurate diagnosis is the most effective way to reduce complications

Staying Ahead With Proactive Health Monitoring

Living with LADA means that your treatment needs will evolve over time. Regular monitoring is not just helpful, it is essential. Tracking your blood sugar, antibody levels, C-peptide function, and other key health markers allows you and your healthcare team to make timely adjustments and stay ahead of complications.

An HbA1c test remains one of the most important tools for monitoring long-term glucose control, alongside other tests that assess kidney function, cholesterol, and thyroid health. Regular testing gives you a clearer picture of how your body is responding and where your care plan may need to be updated.

Metropolis Healthcare offers over 4,000 tests, including speciality panels for diabetes monitoring, autoimmune markers, and comprehensive health screening. With home sample collection available across a wide network of touchpoints, staying on top of your health has never been more convenient. Book easily through the website, app, call, or WhatsApp, and receive accurate, reliable results from NABL and CAP-accredited laboratories with quick turnaround times.

Proactive, regular health monitoring is one of the most empowering things you can do when living with a condition like LADA.

Frequently Asked Questions

Is LADA Type 1 or Type 2 Diabetes?

LADA is neither purely Type 1 nor Type 2, which is why it is called Type 1.5 diabetes. Like type 1 diabetes, it is an autoimmune condition in which the immune system destroys insulin-producing beta cells in the pancreas. Like Type 2, it is diagnosed in adulthood and progresses gradually, often allowing for a period without insulin. It requires specific testing, particularly the GAD antibodies test, to distinguish it from Type 2 diabetes, which it closely resembles at first presentation.

What Causes Latent Autoimmune Diabetes in Adults?

LADA is caused by an autoimmune process in which the body mistakenly produces antibodies that attack and destroy the beta cells of the pancreas. This is triggered by a combination of genetic predisposition, involving specific HLA gene variants shared with type 1 diabetes, and environmental factors that activate the immune response. The exact environmental triggers are not fully understood, but viral infections and other immune system stimuli are being studied. Lifestyle factors do not cause LADA, though metabolic factors may sometimes coexist.

What Are the Early Symptoms of LADA?

Early symptoms of LADA include increased thirst, frequent urination, fatigue, blurred vision, and unexplained weight loss. These are similar to the symptoms of Type 2 diabetes, which is why LADA is so frequently misdiagnosed. Signs that may suggest LADA rather than Type 2 include being lean or of normal weight, having a personal or family history of autoimmune conditions, and experiencing symptoms that progress faster than expected despite oral medication and lifestyle changes.

Can You Live a Long Life With LADA?

Yes. Having LADA does not in itself shorten life expectancy. The key factor is how well blood sugar is managed over time. Poorly controlled blood sugar increases the risk of cardiovascular disease, kidney damage, and other complications that can affect lifespan. With the right diagnosis, appropriate insulin therapy, consistent monitoring, and healthy lifestyle habits, people with LADA can live full, healthy lives.

Can LADA Diabetes Be Cured?

Currently, there is no cure for LADA. Because it is an autoimmune condition, the immune-mediated destruction of beta cells cannot be stopped or reversed with existing treatments. Management focuses on replacing the insulin the pancreas can no longer produce and maintaining stable blood sugar to prevent complications. Research into immunotherapy and beta cell preservation is ongoing, and future treatments may offer new options.

Is Insulin Always Required in LADA?

Not immediately, but almost always eventually. In the early stages of LADA, when some beta cell function remains, oral medications may help manage blood sugar. However, as the autoimmune process continues and more beta cells are destroyed, insulin production declines to the point where insulin therapy becomes necessary. Most people with LADA require insulin within five years of diagnosis. Some specialists recommend starting insulin therapy early to help protect remaining beta cells.

How Fast Does LADA Progress?

LADA progresses more slowly than type 1 diabetes but faster than Type 2. The rate varies between individuals. Some people remain insulin-independent for only a few months after diagnosis, while others manage without insulin for several years. By definition, people with LADA do not require insulin for at least six months after diagnosis. Regular monitoring of C-peptide levels and blood sugar control helps track how quickly beta cell function is declining and when insulin therapy should begin.

What Diet Is Best for LADA Diabetes?

A balanced diet that supports stable blood sugar is important for LADA management. This includes prioritising complex carbohydrates such as whole grains, legumes, and vegetables over refined sugars and processed foods. Adequate protein at each meal helps slow glucose absorption and supports muscle health. Healthy fats from sources such as nuts, seeds, and oily fish are beneficial. Eating regular meals at consistent times helps reduce blood sugar variability. As insulin therapy becomes part of the picture, dietary choices need to be coordinated with insulin dosing, ideally with guidance from a registered dietitian.

Is LADA a Serious Condition?

Yes, LADA is a serious condition that requires accurate diagnosis and appropriate medical management. The greatest risk comes from misdiagnosis, which can leave blood sugar poorly controlled for years and increase the risk of long-term complications affecting the kidneys, eyes, heart, and nerves. With correct identification, timely transition to insulin therapy, and consistent monitoring, however, LADA is a manageable condition and its complications are significantly reducible.

What Is the Difference Between Type 1 Diabetes and LADA?

Both type 1 diabetes and LADA are autoimmune conditions involving the immune system's destruction of insulin-producing beta cells. The key differences lie in age of onset and rate of progression. Type 1 typically presents in childhood or adolescence with rapid, severe beta cell destruction, often requiring immediate insulin therapy. LADA presents in adulthood, usually between 30 and 50, and progresses slowly, allowing for a period of insulin independence after diagnosis. People with LADA are also more likely to be initially misdiagnosed with Type 2 diabetes, as their presentation is far less acute than classic Type 1.

References

1. Laugesen E, Ostergaard JA, Leslie RDG, et al. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med. 2015;32(7):843-852. PMID: 25601320.
2. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206-2212. PMID: 16187040.
3. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48(1):150-157. PMID: 9892237.
4. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med. 1994;11(3):299-303. PMID: 8033528.
5. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1):S1-S321.
6. Mishra R, Hodge KM, Cousminer DL, et al. A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol Metab. 2018;29(9):638-650. PMID: 30041849.
7. World Health Organization. Classification of Diabetes Mellitus. Geneva: WHO; 2019.
8. Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab. 2007;18(2):52-57. PMID: 17208472.